BMJ Open Wilhelm-Benartzi, C S, Miller, S E, Bruggraber, S, Picton, D, Wilson, M, Gatley, K, Chhabra, A, Marcovecchio, M L, Hendriks, A E J, Morobé, H, Chmura, P J, Bond, S, Aschemeier-Fuchs, B, Knip, M, Tree, T, Overbergh, L, Pall, J, Arnaud, O, Haller, M J, Nitsche, A, Schulte, A M, Mathieu, C, Mander, A & Dunger, D 2021, ' Study protocol Minimum effective low dose: Anti-human thymocyte globulin (MELD-ATG) : Phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes ', BMJ Open, vol. 11, no. 12, e053669 . https://doi.org/10.1136/bmjopen-2021-053669 BMJ OPen